Lexaria Bioscience Corp
NASDAQ:LEXX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lexaria Bioscience Corp
NASDAQ:LEXX
|
CA |
|
R
|
Reckitt Benckiser Group PLC
SWB:3RBB
|
UK |
|
S
|
Sanofi SA
XMUN:SNW
|
FR |
|
U
|
UPM-Kymmene Oyj
SWB:RPL
|
FI |
|
A
|
Accenture PLC
SWB:CSA
|
IE |
|
BAE Systems PLC
OTC:BAESY
|
UK |
|
N
|
Norfolk Southern Corp
XMUN:NFS
|
US |
|
C
|
Comcast Corp
F:CTP2
|
US |
|
H
|
Honeywell International Inc
XHAM:ALD
|
US |
|
S
|
Silgan Holdings Inc
SWB:SL3
|
US |
|
InCoax Networks AB
F:86M
|
SE |
|
S
|
Swire Properties Ltd
OTC:SWPFF
|
HK |
|
P
|
PagerDuty Inc
F:2TY
|
US |
|
Intel Corp
SIX:INTC
|
US |
|
Nippon Yusen KK
F:NYK
|
JP |
|
G
|
Groep Brussel Lambert NV
XMUN:EAI
|
BE |
Wall St Price Targets
LEXX Price Targets Summary
Lexaria Bioscience Corp
According to Wall Street analysts, the average 1-year price target for
LEXX is 3.83 USD with a low forecast of 1.52 USD and a high forecast of 6.3 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LEXX's stock price target?
Price Target
3.83
USD
According to Wall Street analysts, the average 1-year price target for
LEXX is 3.83 USD with a low forecast of 1.52 USD and a high forecast of 6.3 USD.
What is the Revenue forecast for Lexaria Bioscience Corp?
Projected CAGR
129%
Over the last 10 years, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 7 years is 129%.
What is the Gross Profit forecast for Lexaria Bioscience Corp?
Projected CAGR
32%
The compound annual growth rate for Gross Profit over the next 3 years is 32%.